Aravive Inc logo

ARAV - Aravive Inc Share Price

$5.37 0.2  3.7%

Last Trade - 03/04/20

Sector
Healthcare
Size
Small Cap
Market Cap £65.8m
Enterprise Value £12.6m
Revenue £3.88m
Position in Universe 4050th / 6308
Bullish
Bearish
Unlock ARAV Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ARAV Revenue Unlock ARAV Revenue

Net Income

ARAV Net Income Unlock ARAV Revenue

Normalised EPS

ARAV Normalised EPS Unlock ARAV Revenue

PE Ratio Range

ARAV PE Ratio Range Unlock ARAV Revenue

Dividend Yield Range

ARAV Dividend Yield Range Unlock ARAV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARAV EPS Forecasts Unlock ARAV Revenue
Profile Summary

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated December 10, 2008
Public Since March 20, 2014
No. of Shareholders: 32
No. of Employees: 17
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 15,015,932
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ARAV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ARAV
Upcoming Events for ARAV
Wednesday 6th May, 2020 Estimate
Q1 2020 Aravive Inc Earnings Release
Wednesday 5th August, 2020 Estimate
Q2 2020 Aravive Inc Earnings Release
Friday 11th September, 2020 Estimate
Aravive Inc Annual Shareholders Meeting
Similar to ARAV
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.